Skip to main content
Erschienen in: Journal of Neurology 10/2014

01.10.2014 | Original Communication

Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology

verfasst von: Masaki Kobayashi, Yuko Shimizu, Noriyuki Shibata, Shinichiro Uchiyama

Erschienen in: Journal of Neurology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Tumefactive demyelinating lesions (TDLs) can mimic brain tumors on radiological images. TDLs are often referred to as tumefactive multiple sclerosis (TMS), but the heterogeneous nature and monophasic course of TDLs do not fulfill clinical and magnetic resonance imaging (MRI) criteria for multiple sclerosis. Redefining TDLs, TMS and other inflammatory brain lesions is essential for the accurate clinical diagnosis of extensive demyelinating brain lesions. We retrospectively analyzed MRI from nine TDL cases that underwent brain biopsy. Patterns of gadolinium enhancement on MRI were categorized as homogenous, inhomogeneous, patchy and diffuse, open ring or irregular rim, and were compared with pathological hallmarks including demyelination, central necrosis, macrophage infiltration, angiogenesis and perivascular lymphocytic cuffing. All cases had coexistence of demyelinating features and axonal loss. Open-ring and irregular rim patterns of gadolinium enhancement were associated with macrophage infiltrations and angiogenesis at the inflammatory border. An inhomogeneous pattern of gadolinium enhancement was associated with perivascular lymphocytic cuffing. Central necrosis was seen in cases of severe multiple sclerosis and hemorrhagic leukoencephalopathy. These results suggest that the radiological features of TDLs may be related to different pathological processes, and indicate that MRI may be useful in understanding their pathophysiology. Further investigation is needed to determine the precise disease entity of these inflammatory demyelinating brain lesions.
Literatur
1.
Zurück zum Zitat Lucchinetti CF, Gavrilova RH, Metz I et al (2008) Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131:1759–1775PubMedCentralCrossRefPubMed Lucchinetti CF, Gavrilova RH, Metz I et al (2008) Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131:1759–1775PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Siva A (2006) The spectrum of multiple sclerosis and treatment decisions. Clin Neurol Neurosurg 108:333–338CrossRefPubMed Siva A (2006) The spectrum of multiple sclerosis and treatment decisions. Clin Neurol Neurosurg 108:333–338CrossRefPubMed
3.
Zurück zum Zitat Dagher AP, Smirniotopoulos J (1996) Tumefactive demyelinating lesions. Neuroradiology 38:560–565CrossRefPubMed Dagher AP, Smirniotopoulos J (1996) Tumefactive demyelinating lesions. Neuroradiology 38:560–565CrossRefPubMed
4.
Zurück zum Zitat Kiriyama T, Kataoka H, Taoka T et al (2011) Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm. J Neuroimaging 21:e69–e77CrossRefPubMed Kiriyama T, Kataoka H, Taoka T et al (2011) Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm. J Neuroimaging 21:e69–e77CrossRefPubMed
5.
Zurück zum Zitat Brück W, Bitsch A, Kolenda H et al (1997) Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 42:783–793CrossRefPubMed Brück W, Bitsch A, Kolenda H et al (1997) Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 42:783–793CrossRefPubMed
6.
Zurück zum Zitat Nesbit GM, Forbes GS, Scheithauer BW et al (1991) Multiple sclerosis: histopathological and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 180:467–474CrossRefPubMed Nesbit GM, Forbes GS, Scheithauer BW et al (1991) Multiple sclerosis: histopathological and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 180:467–474CrossRefPubMed
7.
Zurück zum Zitat Takahashi T, Fujihara K, Nakashima I et al (2006) Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 210:307–313CrossRefPubMed Takahashi T, Fujihara K, Nakashima I et al (2006) Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 210:307–313CrossRefPubMed
8.
Zurück zum Zitat Noseworthy JH, Lucchinetti C, Rodrequez M et al (2000) Multiple sclerosis. N Engl J Med 343:938–952CrossRefPubMed Noseworthy JH, Lucchinetti C, Rodrequez M et al (2000) Multiple sclerosis. N Engl J Med 343:938–952CrossRefPubMed
9.
Zurück zum Zitat Wingerchuk DM, Lennon VA, Lucchinetti CF et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815CrossRefPubMed Wingerchuk DM, Lennon VA, Lucchinetti CF et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815CrossRefPubMed
10.
Zurück zum Zitat Wingerchuk DM, Hogancamp WF, O’Brien PC et al (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53:1107–1114CrossRefPubMed Wingerchuk DM, Hogancamp WF, O’Brien PC et al (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53:1107–1114CrossRefPubMed
11.
Zurück zum Zitat Tintore M, Rovira A, Rio J et al (2003) New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 60:27–30CrossRefPubMed Tintore M, Rovira A, Rio J et al (2003) New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 60:27–30CrossRefPubMed
12.
Zurück zum Zitat Van Waesberghe JH, Kamphorst W, De Groot CJ et al (1999) Axonal loss in MS lesions: MR insight into substrate of disability. Ann Neurol 46:1289–1293 Van Waesberghe JH, Kamphorst W, De Groot CJ et al (1999) Axonal loss in MS lesions: MR insight into substrate of disability. Ann Neurol 46:1289–1293
13.
Zurück zum Zitat Given CA 2nd, Stevens CS, Lee C (2004) The MRI appearance of tumefactive demyelinating lesions. Am J Radiol 182:195–199 Given CA 2nd, Stevens CS, Lee C (2004) The MRI appearance of tumefactive demyelinating lesions. Am J Radiol 182:195–199
14.
Zurück zum Zitat Walner-Blazek M, Rovira A, Filippi M et al (2013) Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol 260:2016–2022CrossRef Walner-Blazek M, Rovira A, Filippi M et al (2013) Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol 260:2016–2022CrossRef
15.
Zurück zum Zitat Rossi A (2008) Imaging of acute disseminated encephalomyelitis. Neuroimaging Clin N Am 18:149–161CrossRefPubMed Rossi A (2008) Imaging of acute disseminated encephalomyelitis. Neuroimaging Clin N Am 18:149–161CrossRefPubMed
16.
Zurück zum Zitat Young NP, Weinshenker BG, Parisi JE et al (2010) Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain 133:333–348PubMedCentralCrossRefPubMed Young NP, Weinshenker BG, Parisi JE et al (2010) Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain 133:333–348PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Gibbs WN, Kreidie MA, Kim RC et al (2005) Acute hemorrhagic leukoencephalitis neuroimaging features and neuropathologic diagnosis. J Comput Assist Tomogr 29:689–693CrossRefPubMed Gibbs WN, Kreidie MA, Kim RC et al (2005) Acute hemorrhagic leukoencephalitis neuroimaging features and neuropathologic diagnosis. J Comput Assist Tomogr 29:689–693CrossRefPubMed
18.
Zurück zum Zitat Xia L, Lin S, Wang ZC et al (2009) Tumefactive demyelinating lesions: nine cases and a review of the literature. Neurosurg Rev 32:171–179CrossRefPubMed Xia L, Lin S, Wang ZC et al (2009) Tumefactive demyelinating lesions: nine cases and a review of the literature. Neurosurg Rev 32:171–179CrossRefPubMed
19.
Zurück zum Zitat Morrissey SP, Stodal H, Zettl U et al (1996) In vivo MRI and its histological correlations in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and edema. Brain 119:239–248CrossRefPubMed Morrissey SP, Stodal H, Zettl U et al (1996) In vivo MRI and its histological correlations in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and edema. Brain 119:239–248CrossRefPubMed
20.
Zurück zum Zitat Schwartz KM, Erickson BJ, Lucchinetti CF (2006) Pattern of T2 hypointensity associated with ring-enhancing brain lesions can help to differentiate pathology. Neuroradiology 48:143–149CrossRefPubMed Schwartz KM, Erickson BJ, Lucchinetti CF (2006) Pattern of T2 hypointensity associated with ring-enhancing brain lesions can help to differentiate pathology. Neuroradiology 48:143–149CrossRefPubMed
21.
Zurück zum Zitat Kirk SL, Karlik SJ (2003) VEGF and vascular changes in chronic neuroinflammation. J Autoimmune 21:353–363CrossRef Kirk SL, Karlik SJ (2003) VEGF and vascular changes in chronic neuroinflammation. J Autoimmune 21:353–363CrossRef
22.
Zurück zum Zitat Su JJ, Osoegawa M, Matsuoka T et al (2006) Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. J Neurol Sci 243:21–30CrossRefPubMed Su JJ, Osoegawa M, Matsuoka T et al (2006) Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. J Neurol Sci 243:21–30CrossRefPubMed
23.
Zurück zum Zitat Proesholdt MA, Jacobson S, Tresser N et al (2002) Vascular endothelial growth factor is expressed in multiple sclerosis plaque and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 61:914–925 Proesholdt MA, Jacobson S, Tresser N et al (2002) Vascular endothelial growth factor is expressed in multiple sclerosis plaque and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 61:914–925
24.
Zurück zum Zitat Sorensen TL, Ransohoff RM, Strieter RM et al (2004) Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. Eur J Neurol 11:445–449CrossRefPubMed Sorensen TL, Ransohoff RM, Strieter RM et al (2004) Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. Eur J Neurol 11:445–449CrossRefPubMed
25.
Zurück zum Zitat Kobayashi M, Ono Y, Shibata N et al (2009) Correlation between magnetic resonance imaging findings and pathological observations in tumefactive multiple sclerosis. Neuroradiol J 22:155–163CrossRefPubMed Kobayashi M, Ono Y, Shibata N et al (2009) Correlation between magnetic resonance imaging findings and pathological observations in tumefactive multiple sclerosis. Neuroradiol J 22:155–163CrossRefPubMed
Metadaten
Titel
Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology
verfasst von
Masaki Kobayashi
Yuko Shimizu
Noriyuki Shibata
Shinichiro Uchiyama
Publikationsdatum
01.10.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 10/2014
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7437-1

Weitere Artikel der Ausgabe 10/2014

Journal of Neurology 10/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.